Aripiprazole
- TRADE NAME: Abilify (Bristol-Myers Squibb); Abilitat
- INDICATIONS: Schizophrenia, bipolar I disorder, major depressive disorder, irritability associated with autistic disorder
- CLASS: Antipsychotic, Mood stabilizer
- HALF-LIFE: 75–94 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Alcohol, Atazanavir, Carbamazepine, CYP3A4 inhibitors, Itraconazole, Ketoconazole, Lopinavir, Nelfinavir, Paroxetine, Quinidine
PREGNANCY CATEGORY: C
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Abilify is not approved for the treatment of patients with dementia-related psychosis.
Children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders are at increased risk of suicidal thinking and behavior.
Please login to see the rest of this drug profile
SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OTIC
OCULAR
OTHER
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of aripiprazole in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric